TECX - Tectonic Therapeutic Inc. Market Cap to Sales Volume

Brandmark of Tectonic Therapeutic, Inc. (TECX)

The current P/S ratio helps assess the valuation of Tectonic Therapeutic, Inc. (TECX) through the lens of ESG standards and laboratory bioethics. Environmental sustainability is supported by closed-loop water systems at the plants to minimize the carbon footprint. However, FDA risks and a potential liquidity shortage create uncertainty. The mark characterizes this parameter, correlating market capitalization with the business's actual revenue.

TECX Tectonic Therapeutic Inc. P/S Multiple (07/04/2022 - 11/16/2026)

Metric breakdowns and analytics for Tectonic Therapeutic, Inc. (TECX)

- share price and consensus valuation forecast:
Fundamental company analysis:Tectonic (TECX)
Brand item of Tectonic

When constructing a long-term portfolio, fundamental screening requires an analysis of the ratio of a business's market value to its annual turnover. This coefficient measures the premium investors are willing to pay per unit of revenue, which is critically important for Tectonic Therapeutic, Inc. (TECX) in the context of penetrating the complex protein target market, reflecting the valuation dynamics of the company's potential through its current P/S ratio.

Competing companies

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Liquidia Technologies|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|P/S Multiple MNKD (MannKind Corp)|Price-to-Revenue Coefficient Amphastar (AMPH)|PCRX: Market Cap to Revenue|SPRY - P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Revenue Ratio|SCPH (scpharmaceuticals.com) - P/S Multiple|P/S Multiple Tonix Pharma|Market Cap to Revenue SXTC (SXT Pharmaceuticals)|EPRX: Price-to-Sales Ratio|BioHarvest Sciences - Market Cap to Revenue|EXOZ: Market Cap to Revenue Ratio|ORMP - Price-to-Revenue Ratio|ENTX: Price-to-Revenue Ratio|HYFT: P/S Multiple|Market Cap to Revenue ABVC BioPharma Inc|CPIX (Cumberland Corp) - P/S Multiple|P/S Multiple quantumbiopharma.com|P/S Multiple FGEN|Market Cap to Revenue Telomir Pharmaceuticals, Inc. TELO|P/S Multiple RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Price-to-Sales Ratio|RLYB: Market Cap to Revenue|lexariabioscience.com (LEXX) - Market Cap to Revenue|Pulmatrix Inc (PULM) - Price-to-Revenue Ratio|PTHL: Market Cap to Sales Volume|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)